Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$4.97
$4.56
$3.20
$28.60
$48.67M0.27438,767 shsN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$0.36
$0.05
$11.78
$5.07M1.2434.54 million shs23.06 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$41.40
+2.0%
$44.78
$20.08
$57.28
$1.71B0.83699,860 shs399,142 shs
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$7.93
-0.1%
$4.93
$1.31
$7.95
$370.57M3.43747,985 shs1.13 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.00%0.00%-0.40%+29.09%-72.36%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00%0.00%0.00%0.00%0.00%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-0.12%-1.67%-5.54%-20.90%+55.67%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
+0.25%+0.76%+0.63%+353.71%+105.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.6324 of 5 stars
3.15.00.00.00.01.71.3
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
1.9687 of 5 stars
3.50.00.00.02.12.50.6
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.5528 of 5 stars
4.05.00.00.01.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.25
Hold$44.60797.38% Upside
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
0.00
N/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
3.00
Buy$66.6761.03% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8036.19% Upside

Current Analyst Ratings Breakdown

Latest BLUE, VIGL, NSTG, and TARS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
5/28/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$11.00 ➝ $8.00
5/27/2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$72.00
5/27/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$14.00 ➝ $8.00
5/23/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Neutral$8.00
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$103.95M0.47N/AN/A$35.59 per share0.14
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
$127.26M0.00N/AN/A$0.98 per share0.00
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$182.95M9.51N/AN/A$5.87 per share7.05
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$1.75 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
-$159.54M-$3.53N/AN/AN/A-102.44%-548.25%-53.79%N/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$115.55M-$2.73N/AN/AN/A-44.91%-39.72%-25.74%8/6/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%8/12/2025 (Estimated)

Latest BLUE, VIGL, NSTG, and TARS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.53-$0.49+$0.04-$0.49N/AN/A
5/1/2025Q1 2025
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bluebird bio, Inc. stock logo
BLUE
bluebird bio
N/AN/AN/AN/AN/A
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/AN/AN/AN/AN/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.37
0.51
0.33
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
2.73
2.02
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
5.57
5.54
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
2.97
2.97

Institutional Ownership

CompanyInstitutional Ownership
bluebird bio, Inc. stock logo
BLUE
bluebird bio
87.43%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
N/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%

Insider Ownership

CompanyInsider Ownership
bluebird bio, Inc. stock logo
BLUE
bluebird bio
1.40%
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
3.10%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
8.97%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
bluebird bio, Inc. stock logo
BLUE
bluebird bio
5209.79 million9.59 millionOptionable
NanoString Technologies, Inc. stock logo
NSTG
NanoString Technologies
55048.12 million46.63 millionOptionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5042.01 million38.25 millionOptionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4046.67 million38.27 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
bluebird bio stock logo

bluebird bio NASDAQ:BLUE

$4.97 0.00 (0.00%)
As of 06/2/2025

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

NanoString Technologies stock logo

NanoString Technologies NASDAQ:NSTG

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$41.40 +0.80 (+1.97%)
Closing price 04:00 PM Eastern
Extended Trading
$40.58 -0.81 (-1.97%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$7.93 -0.01 (-0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$7.94 +0.00 (+0.06%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.